Literature DB >> 6315447

Regulation of calcium-regulating hormones by exogenous sex steroids in early postmenopause.

J C Stevenson, G Abeyasekera, C J Hillyard, K G Phang, I MacIntyre, S Campbell, G Lane, P T Townsend, O Young, M I Whitehead.   

Abstract

A major function of calcitonin in humans appears to be maintenance of the skeleton. There is a marked sex difference in circulating calcitonin levels: women have much lower levels. This has led to speculation that calcitonin lack may be one factor involved in the pathogenesis of postmenopausal bone loss. We have measured levels of calcitonin and the other major calcium-regulating hormones in healthy women during the early menopause, and studied the effects of reversing their oestrogen deficiency with natural and synthetic oestrogen. The major findings were that calcitonin levels were increased by oestrogen administration (P less than 0.02-less than 0.001) and that the levels of the bone-resorbing hormones, parathyroid hormone and 1,25 dihydroxyvitamin D, were not higher in postmenopausal than in premenopausal women. We suggest that loss of oestrogen at the menopause accelerates the natural age-related decline of calcitonin secretion, thus further decreasing the calcitonin levels. This leads to increased sensitivity of the skeleton to the actions of the bone-resorbing hormones. It seems likely that the well-known effect of oestrogen in preventing postmenopausal bone loss is achieved, at least in part, by enhancement of calcitonin secretion.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6315447     DOI: 10.1111/j.1365-2362.1983.tb00133.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  10 in total

Review 1.  A risk-benefit assessment of estrogen therapy in postmenopausal women.

Authors:  M P Cust; K F Gangar; T C Hillard; M I Whitehead
Journal:  Drug Saf       Date:  1990 Sep-Oct       Impact factor: 5.606

Review 2.  [Principles of estrogen therapy].

Authors:  H P Schneider
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

Review 3.  Role of oestrogen in the development of osteoporosis.

Authors:  T C Hillard; J C Stevenson
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

Review 4.  Estrogens, bone loss and preservation.

Authors:  C Christiansen; R Lindsay
Journal:  Osteoporos Int       Date:  1990-10       Impact factor: 4.507

5.  Dose dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women.

Authors:  M I Whitehead; N M Shennan; J C Stevenson
Journal:  Br Med J (Clin Res Ed)       Date:  1987-03-21

6.  Effect of salcatonin given intranasally on early postmenopausal bone loss.

Authors:  K Overgaard; B J Riis; C Christiansen; M A Hansen
Journal:  BMJ       Date:  1989-08-19

7.  Calcitonin metabolism in senile (type II) osteoporosis.

Authors:  J Y Reginster; R Deroisy; M Bruwier; P Franchimont
Journal:  Osteoporos Int       Date:  1992-05       Impact factor: 4.507

8.  Lack of hormonal changes in postmenopausal women of equal weight with and without osteoporosis, including relation to time of menopause.

Authors:  H Rico; A Charro; I Depablos; E Bordiu; E R Hernandez; D Espinos
Journal:  Clin Rheumatol       Date:  1984-09       Impact factor: 2.980

9.  Measurement of estrogen and progesterone receptors in abnormal human parathyroid tissue.

Authors:  A W Saxe; G W Gibson; I H Russo; P Gimotty
Journal:  Calcif Tissue Int       Date:  1992-11       Impact factor: 4.333

10.  Relationship between whole plasma calcitonin levels, calcitonin secretory capacity, and plasma levels of estrone in healthy women and postmenopausal osteoporotics.

Authors:  J Y Reginster; R Deroisy; A Albert; D Denis; M P Lecart; J Collette; P Franchimont
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.